tumor antigen 中文意思是什麼

tumor antigen 解釋
腫瘤抗原
  • tumor : n. 【醫學】腫瘤，癌，疙瘩，贅疣。 a benign [malignant] tumor 良[惡]性腫瘤。adj. -ous 腫瘤的；誇張的 （tumorous growth 【農業】陡長）。
  • antigen : n. 【醫學】抗原。
  1. Antigen density on the tumor cell surface influences the cytotoxic sensitivity.

    瘤細胞表面的抗原密度影響細胞毒的敏感性。
  2. Heat shock proteins ( hsps ) are molecular chaperones with potent adjuvant capability in the induction of antigen - specific ctl, thl response and increasing immunogenicity of tumor cells

    本課題應用a20腫瘤細胞，經熱休克作用，制備熱休克腫瘤細胞來源的exosomes 。
  3. Cells of the immune system taking part in tumor - host interaction include t cells, natural killer cells ( nk cells ) and antigen - presenting cells ( apc, such as dendritic cells, b cells, macrophages )

    參與腫瘤免疫的免疫細胞主要有t細胞， nk細胞和抗原提呈細胞（ apc ） 。
  4. At present, in an attempt to stimulate specific antitumor immunity, experimental models and clinical studies are currently evaluating the potent antigen - presenting capacity of dc combined with single or multiple tumor antigen epitopes. however, there are several problems in utilizing pulsing dc with synthetic immunodominant peptides from identified antigens. 1 ) the potential induction of tolerance ; 2 ) the need to determine the patient ' s hla haplotype, the limitation of therapy to patients whose tumors express defined specific tumor antigens in the context of the correct hla phenotype, the unavailability of peptides for all hla haplotypes ; 3 ) the lack of cd4 help cell - related epitopes for most antigens ; and 4 ) the ctl resulting from such protocols have a good in vitro capacity to kill peptide - pulsed target cells but only a modest capacity to kill tumor cells

    但是，學者們發現這一療法存在著如下的缺陷：單一ctl表位抗原肽的應用其抗腫瘤作用弱於多種腫瘤抗原的聯合應用，且有誘導免疫耐受的潛在危險，有時反而會促進腫瘤的生長；事先需對患者的hla單倍型進行鑒定，以確定ctl表位與hla單倍型是否匹配，目前尚缺乏能與所有hla單倍型相匹配的ctl表位，從而限制了這一療法的應用；這一療法所產生的ctl在體外能有效殺傷經腫瘤抗原肽共孵育過的靶細胞，但對腫瘤細胞的殺傷能力較弱：這種l表位抗原肽缺乏cd4汀h細胞相關的表位，因此，不能誘導有效的th細胞免疫應答。
  5. Dendritic cells ( dc ), the initiator and modulator of immune response, are the most powerful professional antigen - presenting cells ( apc ). recent studies indicated that dc have the most power to activate tumor specific ctl, therefore, dc are applied in the therapy of tumors, e

    機體的抗腫瘤免疫主要為t淋巴細胞所介導， t細胞的致敏、激活、擴增和對腫瘤細胞的殺傷作用均有賴于抗原遞呈細胞腫瘤遞呈相應的抗原肽及相關因子的參與。
  6. Dcs play a pivotal role in the development of antitumor immunity. t lymphocytes immune response induced by direct antigen - pulsed dcs can not maintain longer for peptides - mhc department or mhc molecules degeneration. the method of dcs loading with tumor antigen gene is another potential approach to enhancing and maintaining immune response

    在用抗原直接刺激dc時，由於抗原- mhc復合物解離或細胞mhc分子降解而不能維持所誘導的t細胞免疫應答，藉助載體把腫瘤抗原基因導入dc后腫瘤抗原在dc內的持續表達能增強其抗原提呈能力並能維持所誘導的免疫效應。
  7. Objective from 1990s, the successful cloning of many tumor antigen genes of human kind has driven the development of tumor immunology enormously. and so does it to the application of tumor immunodiagno sties and immunotherapy

    目的： 20世紀90年代以來，多種人類腫瘤抗原基因克隆的成功，大大推動了腫瘤免疫學理論的發展，也促進了腫瘤免疫診斷和免疫治療的應用。
  8. Though with various advantages, these tumor vaccines are because of complicated to prepare, restricted availability of relevant tumor antigens, the lack of molecularly defined tumor antigen delivery or targeting systems and the effects are relatively not promising

    這些腫瘤疫苗的制備機理均在於提高對腫瘤抗原的遞呈作用。缺點是制備工藝復雜、效果相對不夠理想。 exosomes是由多種細胞分泌的來源於多囊泡體的小的膜性囊泡。
  9. To circumvent these deficits, novel antigen - delivery systems utilizing cytokine gene - modified tumor cells and dc or fusion of dc with tumor cells have resulted in induction of antitumor immunity. however, this u approach is difficult in some cases ( for example in breast cancer ) because only rarely has it been possible to isolate enough viable tumor cells from an individual to prepare the vaccine

    為了克服上述缺陷，有學者採用滅活的腫瘤細胞、腫瘤抗原提取物（包括腫瘤細胞裂解物、 it na和洗脫肽等）沖擊致敏dc或將腫瘤細胞與dc融合后再回輸體內以激發機體的抗腫瘤免疫應答，也取得了較好的療效。
  10. Methods employed to prepare vaccine include rumor cells genetically modified with cytokines, costimulatory molecules and tumor antigenic peptides, dendritic cells ( dc ) primed with tumor antigens in vitro or genetically modified with tumor antigens, or fusion of tumor cells with antigen presenting cells ( apc )

    現有的比較受到關注的制備腫瘤疫苗的方法有各種細胞因子、共刺激分子、腫瘤抗原肽等基因修飾的腫瘤細胞疫苗；體外抗原致敏的或腫瘤抗原肽基因修飾的樹突狀細胞疫苗；腫瘤細胞與抗原遞呈細胞融合疫苗等。
  11. It delivers the false ? folding peptides for presentation to proteasomes in normal cells, while in tumor cells it acts as main tumor - resistant antigen, inducing specific immune response. recent research found that grp94 also relates with cell cycles, differentiation and apoptosis

    此外發現它還具有抗原提呈作用，在正常細胞中參與折疊錯誤蛋白到蛋白酶體的提呈；在腫瘤細胞中作為主要的腫瘤排斥抗原，引發針對該腫瘤細胞的特異性免疫反應。
  12. Preparation of carcinoembryonic antigen positive tumor gene vaccine capsules for oral use

    癌胚抗原腫瘤基因疫苗膠囊的研製
  13. The study lays a foundation for further application of the expressed product in expansion of hematopoietic stem cells and tumor immunotherapy. last, recobinant human fl can be used to generate large numbers of antigen - presenting dendritic cells from cd34 + peripheral blood progenitor cells that might be ideally used for immunotherapeutic approaches

    綜上所述，本實驗根據畢赤氏酵母偏愛密碼子構建了高效分泌表達fl的工程菌株，其分泌表達的重組fl蛋白具有與天然蛋白相似的生物學功能，為獲取大量重組fl蛋白，進一步研究fl的生物功能奠定了工作基礎。
  14. Cea is probably the most extensively characterized human tumor associated antigen. it was discovered in colorectal and pancreatic carcinomas in 1965 and it " s full cdna was cloned in 1987. it is a kind of glycoprotein and it " s molecular weight is 180kd

    癌胚抗原（ carcinoembryonicantigencea ）是一種最常見的腫瘤相關抗原（ taa ） ，也是國際上公認的腫瘤標志物，於1965年首次在人結腸癌和胰腺癌中發現， 1987年克隆出它的全長基因序列。
  15. Conclusion : apoptotic - tumor - cell - loaded dc induced maturation by cd40mab could efficiently induce the activation and proliferation of tumor specific ctl, and the combination of il - 2, il - 15, cd28mab was a very powerful method to expand antigen specific ctl in vitro

    結論： cd40mab激發的凋亡腫瘤細胞負載dc在cd28mab 、 ilj和il上的聯合作用下可有效激活和擴增腫瘤特異性cth 。
  16. Activated dc cells promote the antigen to repress tumor metastasis, the breakdown product of cancer cellular necrosis also exciting immunologic system

    活化dc細胞促進抗原呈抑制腫瘤轉移，壞死癌細胞分解產物刺激增強免役系統
  17. Objectives firstly to prepare the vaccine of human dcs and tumor cells transfectde with pcdna3 - cea, and to observe the induction of carcinoembryonic antigen ( cea ) - specific cytotoxic t - lymphocyte responses in vitro

    用脂質體將cea表達質粒轉染人dc ，觀察其對cea表達陽性的腫瘤的特異性免疫作用。
  18. 2. the plasimd encoding human carcinoembryonic antigen was transfected with lipofectine into human dcs and human tumor cells such as mgc803, ls174t and eel09. the culture supernatants were collected for assaying carcinoembryonic antigen by. 3

    1640培養液中，在37ac ， 5 co ，的培養箱內培養， 』每3心傳代一次，取對數生長期的細胞進行實驗。
  19. Study of immunity of epitope of tumor special antigen displayed on a filamentous bacteriophage

    噬菌體展示腫瘤異性抗原表位的初步免疫活性研究
  20. Filamentous bacteriophage displayed tumor - specific antigen epitope mage - a1 induced cellular immune in mice

    展示腫瘤特異性抗原表位的噬菌體在小鼠體內引起的細胞免疫變化
分享友人
分享到 Line

分享到臉書